We therefore conducted a prospective trial to evaluate detection of recurrent prostate cancer by simultaneous 18F-fluciclovine PET/MRI with a special focus on low PSA levels (≤1ng/mL). The gene discussed is KLK3; the disease is prostate carcinoma.